MedTrace Logo

A Risky Sex Prevention Intervention for Middle School Age Minority Girls

NCT02103218 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 212

Last updated 2021-06-16

Study results available
· View outcomes & findings →

Summary

African American adolescent females are more likely to have sex at an early age, to have older sex partners that have had multiple sexual experiences, and are less likely to use a condom than their white counterparts. Lack of sexual assertiveness is a factor in the risky sex behaviors of young African American women. African American girls at the greatest risk for contracting HIV are the ones that report that their partners could convince them to have sex and report trouble communicating their wishes related to sex. Thus far no intervention has addressed the disparate rate of HIV infection in young African American girls. This study is unique in promoting increases in racial pride as a component of empowerment to help African American girls self-protect against HIV. The study has the potential to empower young African American girls to delay sex initiation or reduce risky sex behaviors and thus reduce their risk of contracting HIV.

Conditions

  • HIV
  • Risky Sex Prevention

Interventions

BEHAVIORAL

Education, activities, empowerment, racial pride building

Intervention focuses on information aimed toward reducing or preventing risky sex behaviors of minority adolescent females.

BEHAVIORAL

General Health education, activities

Intervention focuses on information regarding general health knowledge and healthy behaviors (not including sex).

Sponsors & Collaborators

  • University of North Carolina, Greensboro

    lead OTHER

Principal Investigators

  • Tracy R Bartlett, PhD · University of North Carolina, Greensboro

  • Debra C Wallace, PhD · Univeristy of North Carolina, Greensboro

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
11 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2018-02-13
Completion
2018-02-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02103218 on ClinicalTrials.gov